NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

全球基因檢測市場:按類型,技術,應用分列的市場機會分析和行業預測(2020-2027)

Genetic Testing Market by Type, Technology, Application : Global Opportunity Analysis and Industry Forecast, 2020-2027

出版商 Allied Market Research 商品編碼 972136
出版日期 內容資訊 英文 247 Pages
商品交期: 2-3個工作天內
價格
全球基因檢測市場:按類型,技術,應用分列的市場機會分析和行業預測(2020-2027) Genetic Testing Market by Type, Technology, Application : Global Opportunity Analysis and Industry Forecast, 2020-2027
出版日期: 2020年09月30日內容資訊: 英文 247 Pages
簡介

2019年,全球基因檢測市場規模將達到126.82億美元,從2020年到2027年將以10.1%的複合年增長率增長,到2027年將達到212.6億美元。

遺傳測試是對DNA的研究,該DNA可以識別與各種遺傳性疾病相關的遺傳突變。遺傳測試有許多不同的類型,包括用於確定人的染色體,基因或蛋白質變化的幾種方法,例如細胞遺傳測試,生化測試,分子測試和染色體分析。遺傳測試的結果可以幫助識別或診斷可疑的遺傳狀況,或確定發生或遺傳性疾病的可能性。

基因檢測不僅確定患上特定疾病的風險,而且在篩查甚至藥物治療中也起著重要作用。由於多種原因進行了不同類型的基因測試,包括症狀前和預測測試,攜帶者測試,產前測試和新生兒篩查。

由於遺傳性疾病和癌症的發病率上升,以及對定製藥物的認識和接受程度提高,預計全球基因檢測市場未來將出現顯著增長。例如,基因檢測在藥理基因組學中被廣泛使用,也稱為藥物基因檢測。此外,基因檢測技術的進步有望在預測期內促進市場增長。但是,基於基因測試的診斷方法的標準化問題以及對產品批准的嚴格監管要求,預計將在預測期內阻礙市場增長。相反,新興國家尚未開發的新興市場有望為市場參與者提供豐厚的機會。例如,在巴西,印度和中國等新興國家,對醫療保健和基礎設施的投資已大大增加,該地區對基因檢測的需求猛增。

本報告對全球基因檢測市場進行了調查,概述了該市場,按類型,技術,應用和地區劃分的市場規模趨勢和預測,市場趨勢,對增長和抑制因素的分析以及市場機會。它提供了全面的信息,例如競爭狀況和主要公司的概況。

目錄

第1章簡介

第2章執行摘要

第3章市場概述

  • 市場定義和範圍
  • 主要發現
    • 主要投資口袋
  • 波特的五力分析
  • 主要公司的定位,2019年
  • 市場動態
    • 生長促進因素
      • 遺傳性疾病和癌症的發病率增加
      • 提高對定制醫療的認識和接受度
      • 基因檢測技術的進步
    • 抑制因素
      • 基於基因測試的診斷標準化問題
      • 產品批准的嚴格監管要求
    • 市場機會
      • 新興國家中不發達的新興市場
  • 專利分析(2017-2022)
    • 專利分析:按年份
    • 2019年專利分析:按國家

第4章基因檢測市場:按類型

  • 概述
    • 市場規模和預測:按地區
  • 預測和症狀前測試
    • 主要市場趨勢,增長因素和機遇
    • 市場規模和預測:按地區
    • 市場分析:按國家
  • 運營商檢查
    • 主要市場趨勢,增長因素和機遇
    • 市場規模和預測:按地區
    • 市場分析:按國家
  • 產前和新生兒檢查
    • 主要市場趨勢,增長因素和機遇
    • 市場規模和預測:按地區
    • 市場分析:按國家
  • 診斷測試
    • 主要市場趨勢,增長因素和機遇
    • 市場規模和預測:按地區
    • 市場分析:按國家
  • 藥物基因組學測試
    • 主要市場趨勢,增長因素和機遇
    • 市場規模和預測:按地區
    • 市場分析:按國家
  • 其他
    • 主要市場趨勢,增長因素和機遇
    • 市場規模和預測:按地區
    • 市場分析:按國家

第5章基因檢測市場:按技術

  • 概述
    • 市場規模和預測:按地區
  • 細胞遺傳測試/染色體分析
    • 市場規模和預測:按地區
    • 市場分析:按國家
  • 生化測試
    • 市場規模和預測:按地區
    • 市場分析:按國家
  • 分子測試
    • 市場規模和預測:按地區:按類型
      • DNA測序
      • 其他
    • 市場規模和預測:按地區
    • 市場分析:按國家

第6章基因檢測市場:按應用

  • 概述
    • 市場規模和預測
  • 癌症診斷
    • 市場規模和預測
    • 市場分析:按國家
  • 遺傳病的診斷
    • 市場規模和預測
    • 市場分析:按國家
  • 心血管疾病的診斷
    • 市場規模和預測
    • 市場分析:按國家
  • 其他
    • 市場規模和預測
    • 市場分析:按國家

第7章基因檢測市場:按地區

  • 概述
    • 市場規模和預測
  • 北美
    • 主要市場趨勢和機遇
    • 市場規模和預測:按檢驗類型
    • 市場規模和預測:按技術
    • 市場規模和預測:按應用
    • 市場規模和預測:按國家
      • 美國市場規模和預測:按檢驗類型
      • 美國市場規模和預測:按技術
      • 美國市場規模和預測:按應用
      • 加拿大市場規模和預測:按檢驗類型
      • 加拿大市場規模和預測:按技術
      • 加拿大市場規模和預測:按應用
      • 墨西哥市場規模和預測:按檢驗類型
      • 墨西哥市場規模和預測:按技術
      • 墨西哥市場規模和預測:按應用
  • 歐洲
    • 主要市場趨勢,增長因素和機遇
    • 市場規模和預測:按檢驗類型
    • 市場規模和預測:按技術
    • 市場規模和預測:按應用
    • 市場規模和預測:按國家
      • 德國市場規模和預測:按檢驗類型
      • 德國市場規模和預測:按技術
      • 德國市場規模和預測:按應用
      • 法國市場規模和預測:按檢驗類型
      • 法國市場規模和預測:按技術
      • 法國市場規模和預測:按應用
      • 英國市場規模和預測:按檢驗類型
      • 英國市場規模和預測:按技術
      • 英國市場規模和預測:按應用
      • 意大利市場規模和預測:按檢驗類型
      • 意大利市場規模和預測:按技術
      • 意大利市場規模和預測:按應用
      • 西班牙市場規模和預測:按檢驗類型
      • 西班牙市場規模和預測:按技術
      • 西班牙市場規模和預測:按應用
      • 其他歐洲市場規模和預測:按檢驗類型
      • 其他歐洲市場規模和預測:按技術
      • 其他歐洲市場規模和預測:按應用
  • 亞太地區
    • 主要市場趨勢,增長因素和機遇
    • 市場規模和預測:按檢驗類型
    • 市場規模和預測:按技術
    • 市場規模和預測:按應用
    • 市場規模和預測:按國家
      • 日本市場規模和預測:按檢驗類型
      • 日本市場規模和預測:按技術
      • 日本市場規模和預測:按應用
      • 中國市場規模和預測:按檢驗類型
      • 中國市場規模和預測:按技術
      • 中國市場規模和預測:按應用
      • 澳大利亞市場規模和預測:按檢驗類型
      • 澳大利亞市場規模和預測:按技術
      • 澳大利亞市場規模和預測:按應用
      • 印度市場規模和預測:按檢驗類型
      • 印度市場規模和預測:按技術
      • 印度市場規模和預測:按應用
      • 韓國市場規模和預測:按檢驗類型
      • 韓國市場規模和預測:按技術
      • 韓國市場規模和預測:按應用
      • 其他亞太市場規模和預測:按檢驗類型
      • 其他亞太市場規模和預測:按技術
      • 其他亞太市場規模和預測:按應用
  • 拉美
    • 主要市場趨勢,增長因素和機遇
    • 市場規模和預測:按檢驗類型
    • 市場規模和預測:按技術
    • 市場規模和預測:按應用
    • 市場規模和預測:按國家
      • 巴西市場規模和預測:按檢驗類型
      • 巴西市場規模和預測:按技術
      • 巴西市場規模和預測:按應用
      • 沙特阿拉伯市場規模和預測:按檢查類型
      • 沙特阿拉伯市場規模和預測:按技術
      • 沙特阿拉伯市場規模和預測:按應用
      • 南非市場規模和預測:按檢驗類型
      • 南非市場規模和預測:按技術
      • 南非市場規模和預測:按應用
      • 其他LAMEA市場規模和預測:按檢驗類型
      • 其他LAMEA市場規模和預測:按技術
      • 其他LAMEA市場規模和預測:按應用

第8章公司簡介

  • ABBOTT LABORATORIES
  • BIO-RAD LABORATORIES, INC. (RAINDANCE TECHNOLOGIES, INC.)
  • CSL LTD.
  • DANAHER CORPORATION (CEPHEID)
  • EUROFINS SCIENTIFIC
  • F. HOFFMANN-LA ROCHE LTD.
  • ILLUMINA, INC.
  • MYRIAD GENETICS, INC. (MYRIAD RBM, INC.)
  • QIAGEN N.V. (FORMULATRIX, INC.)
  • THERMO FISHER SCIENTIFIC, INC.
目錄
Product Code: A04878

Title:
Genetic Testing Market by Type (Predictive & Presymptomatic Testing, Carrier Testing, Prenatal & Newborn Testing, Diagnostic Testing, Pharmacogenomic Testing, and Others), Technology (Cytogenetic Testing, Biochemical Testing, and Molecular Testing), Application (Cancer diagnosis, Genetic Disease Diagnosis, Cardiovascular Disease Diagnosis, and Others): Global Opportunity Analysis and Industry Forecast, 2020-2027.

The genetic testing market accounted for $ 12,682 million in 2019, and is expected to reach $ 21,260 million by 2027, registering a CAGR of 10.1% from 2020 to 2027.

Genetic testing is the study of DNA that identifies gene mutation associated with a variety of genetic disorders. There are various types of genetic testing and several methods such as cytogenetic testing, biochemical testing, molecular testing, and chromosome analysis used to determine changes in a person's chromosomes, genes, or proteins. The results of a genetic tests confirm or diagnose a suspected genetic condition or help determine a person's chance of developing or passing on a genetic disorder.

Genetic testing plays a vital role in determining the risk of developing certain diseases as well as screening and sometimes medical treatment. Different types of genetic testing are done for different reasons such as presymptomatic and predictive testing, carrier testing, prenatal testing, and newborn screening.

The global genetic testing market is expected to register substantial growth in the future, owing to rise in incidences of genetic disorders and cancer and rise in awareness & acceptance of personalized medicines. For instance, Genetic testing has been widely used in pharmacogenomics, also referred as drug-gene testing. In addition, advancements in genetic testing techniques are expected to boost the market growth during the forecast period. However, standardization concerns of genetic testing-based diagnostics and stringent regulatory requirements for product approvals are anticipated to hamper the market growth during the forecast period. Conversely, untapped emerging markets in developing countries are expected to provide remunerative opportunities for the market players. For instance, Healthcare systems in developing countries such as Brazil, India, and China have experienced significant increase in investments in healthcare and infrastructure which leads to surge in demand for genetic testing in the region.

The global genetic testing market is segmented on the basis of type, technology, application, and region. By type, the market is categorized into predictive & presymptomatic testing, carrier testing, prenatal & newborn testing, diagnostic testing, pharmacogenomic testing, and others. On the basis of technology, it is divided into cytogenetic testing/chromosomal analysis, biochemical testing, and molecular testing. Molecular testing is further classified into DNA sequencing and others. By application, it is segmented into cancer diagnosis, genetic disease diagnosis, cardiovascular disease diagnosis, and others. By region, the genetic testing market size is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

The major players in the genetic testing market are Abbott Laboratories, Bio-Rad Laboratories, Inc. (RainDance Technologies, Inc.), Myriad Genetics, Inc. (Myriad RBM, Inc.), Danaher Corporation (Cepheid), F. Hoffmann-La Roche Ltd., Eurofins Scientific, Illumina, Inc., Qiagen N.V., Thermo Fisher Scientific, Inc., and CSL Ltd.

KEY BENEFITS FOR STAKEHOLDERS

This report entails a detailed quantitative analysis along with the current global negative pressure wound therapy devices market trends from 2019 to 2027 to identify the prevailing opportunities along with the strategic assessments.

The market size and estimations are based on a comprehensive analysis of key developments in the industry.

A qualitative analysis based on innovative products facilitates strategic business planning.

The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market

Key Market Segments

By Type

Predictive & Presymptomatic Testing

Carrier Testing

Prenatal & Newborn Testing

Diagnostic Testing

Pharmacogenomic Testing

Others

By Technology

Cytogenetic Testing

Biochemical Testing

Molecular Testing

By Application

Cancer diagnosis

Genetic Disease Diagnosis

Cardiovascular Disease Diagnosis

Others

By Region

North America

U.S.

Canada

Mexico

Europe

Germany

France

UK

Italy

Spain

Rest of Europe

Asia-Pacific

Japan

China

India

Australia

South Korea

Rest of Asia-Pacific

LAMEA

Brazil

Saudi Arabia

South Africa

Rest of LAMEA

List of key players profiled in the report:

  • Abbott Laboratories
  • Bio-Rad Laboratories, Inc. (RainDance Technologies, Inc.)
  • Myriad Genetics, Inc. (Myriad RBM, Inc.)
  • Danaher Corporation (Cepheid)
  • F. Hoffmann-La Roche Ltd.
  • Eurofins Scientific
  • Illumina, Inc.
  • Qiagen N.V.
  • Thermo Fisher Scientific, Inc.
  • CSL Ltd.
  • LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)
  • PerkinElmer, Inc.
  • Natera
  • Sonic Healthcare

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key benefits for stakeholders
  • 1.3.Key market segments
  • 1.4.Research methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools & models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning, 2019
  • 3.5.Market dynamics
    • 3.5.1.Drivers
      • 3.5.1.1.Increase in incidences of genetic disorders and cancer
      • 3.5.1.2.Rise in awareness & acceptance of personalized medicines
      • 3.5.1.3.Advancements in genetic testing techniques
    • 3.5.2.Restraints
      • 3.5.2.1.Standardization concerns of genetic testing-based diagnostics
      • 3.5.2.2.Stringent regulatory requirements for product approvals
    • 3.5.3.Opportunities
      • 3.5.3.1.Untapped emerging markets in developing countries
  • 3.6.Patent analysis (2017-2022)
    • 3.6.1.Patent analysis, by year
    • 3.6.2.Patent analysis for year 2019, by country

CHAPTER 4:GENETIC TESTING MARKET, BY TYPE

  • 4.1.Overview
    • 4.1.1.Market size and forecast, by region
  • 4.2.Predictive & presymptomatic testing
    • 4.2.1.Key market trends, growth factors, and opportunities
    • 4.2.2.Market size and forecast, by region
    • 4.2.3.Market analysis, by country
  • 4.3.Carrier testing
    • 4.3.1.Key market trends, growth factors, and opportunities
    • 4.3.2.Market size and forecast, by region
    • 4.3.3.Market analysis, by country
  • 4.4.Prenatal and newborn testing
    • 4.4.1.Key market trends, growth factors, and opportunities
    • 4.4.2.Market size and forecast, by region
    • 4.4.3.Market analysis, by country
  • 4.5.Diagnostic testing
    • 4.5.1.Key market trends, growth factors, and opportunities
    • 4.5.2.Market size and forecast, by region
    • 4.5.3.Market analysis, by country
  • 4.6.Pharmacogenomic testing
    • 4.6.1.Key market trends, growth factors, and opportunities
    • 4.6.2.Market size and forecast, by region
    • 4.6.3.Market analysis, by country
  • 4.7.Others
    • 4.7.1.Key market trends, growth factors, and opportunities
    • 4.7.2.Market size and forecast, by region
    • 4.7.3.Market analysis, by country

CHAPTER 5:GENETIC TESTING MARKET, BY TECHNOLOGY

  • 5.1.Overview
    • 5.1.1.Market size and forecast, by region
  • 5.2.Cytogenetic testing/chromosome analysis
    • 5.2.1.Market size and forecast, by region
    • 5.2.2.Market analysis, by country
  • 5.3.Biochemical testing
    • 5.3.1.Market size and forecast, by region
    • 5.3.2.Market analysis, by country
  • 5.4.Molecular testing
    • 5.4.1.Market size and forecast, by region, by type
      • 5.4.1.1.DNA Sequencing
      • 5.4.1.1.1.Market size and forecast, by region
      • 5.4.1.2.Others
      • 5.4.1.2.1.Market size and forecast, by region
    • 5.4.2.Market size and forecast, by region
    • 5.4.3.Market analysis, by country

CHAPTER 6:GENETIC TESTING MARKET, BY APPLICATION

  • 6.1.Overview
    • 6.1.1.Market size and forecast
  • 6.2.Cancer diagnosis
    • 6.2.1.Market size and forecast
    • 6.2.2.Market analysis, by country
  • 6.3.Genetic disease diagnosis
    • 6.3.1.Market size and forecast
    • 6.3.2.Market analysis, by country
  • 6.4.Cardiovascular disease diagnosis
    • 6.4.1.Market size and forecast
    • 6.4.2.Market analysis, by country
  • 6.5.Others
    • 6.5.1.Market size and forecast
    • 6.5.2.Market analysis, by country

CHAPTER 7:GENETIC TESTING MARKET, BY REGION

  • 7.1.Overview
    • 7.1.1.Market size and forecast
  • 7.2.North America
    • 7.2.1.Key market trends and opportunities
    • 7.2.2.Market size and forecast, by test type
    • 7.2.3.Market size and forecast, by technology
    • 7.2.4.Market size and forecast, by application
    • 7.2.5.Market size and forecast, by country
      • 7.2.5.1.U.S. market size and forecast, by test type
      • 7.2.5.2.U.S. market size and forecast, by technology
      • 7.2.5.3.U.S. market size and forecast, by application
      • 7.2.5.4.Canada market size and forecast, by test type
      • 7.2.5.5.Canada market size and forecast, by technology
      • 7.2.5.6.Canada market size and forecast, by application
      • 7.2.5.7.Mexico market size and forecast, by test type
      • 7.2.5.8.Mexico market size and forecast, by technology
      • 7.2.5.9.Mexico market size and forecast, by application
  • 7.3.Europe
    • 7.3.1.Key market trends, growth factors, and opportunities
    • 7.3.2.Market size and forecast, by test type
    • 7.3.3.Market size and forecast, by technology
    • 7.3.4.Market size and forecast, by application
    • 7.3.5.Market size and forecast, by country
      • 7.3.5.1.Germany market size and forecast, by test type
      • 7.3.5.2.Germany market size and forecast, by technology
      • 7.3.5.3.Germany market size and forecast, by application
      • 7.3.5.4.France market size and forecast, by test type
      • 7.3.5.5.France market size and forecast, by technology
      • 7.3.5.6.France market size and forecast, by application
      • 7.3.5.7.UK market size and forecast, by test type
      • 7.3.5.8.UK market size and forecast, by technology
      • 7.3.5.9.UK market size and forecast, by application
      • 7.3.5.10.Italy market size and forecast, by test type
      • 7.3.5.11.Italy market size and forecast, by technology
      • 7.3.5.12.Italy market size and forecast, by application
      • 7.3.5.13.Spain market size and forecast, by test type
      • 7.3.5.14.Spain market size and forecast, by technology
      • 7.3.5.15.Spain market size and forecast, by application
      • 7.3.5.16.Rest of Europe market size and forecast, by test type
      • 7.3.5.17.rest of Europe market size and forecast, by technology
      • 7.3.5.18.Rest of Europe market size and forecast, by application
  • 7.4.Asia-Pacific
    • 7.4.1.Key market trends, growth factors, and opportunities
    • 7.4.2.Market size and forecast, by test type
    • 7.4.3.Market size and forecast, by technology
    • 7.4.4.Market size and forecast, by application
    • 7.4.5.Market size and forecast, by country
      • 7.4.5.1.Japan market size and forecast, by test type
      • 7.4.5.2.Japan market size and forecast, by technology
      • 7.4.5.3.Japan market size and forecast, by application
      • 7.4.5.4.China market size and forecast, by test type
      • 7.4.5.5.China market size and forecast, by technology
      • 7.4.5.6.China market size and forecast, by application
      • 7.4.5.7.Australia market size and forecast, by test type
      • 7.4.5.8.Australia market size and forecast, by technology
      • 7.4.5.9.Australia market size and forecast, by application
      • 7.4.5.10.India market size and forecast, by test type
      • 7.4.5.11.India market size and forecast, by technology
      • 7.4.5.12.India market size and forecast, by application
      • 7.4.5.13.South Korea market size and forecast, by test type
      • 7.4.5.14.South Korea market size and forecast, by technology
      • 7.4.5.15.South Korea market size and forecast, by application
      • 7.4.5.16.Rest of Asia-Pacific market size and forecast, by test type
      • 7.4.5.17.Rest of Asia-Pacific market size and forecast, by technology
      • 7.4.5.18.Rest of Asia-Pacific market size and forecast, by application
  • 7.5.LAMEA
    • 7.5.1.Key market trends, growth factors, and opportunities
    • 7.5.2.Market size and forecast, by test type
    • 7.5.3.Market size and forecast, by technology
    • 7.5.4.Market size and forecast, by application
    • 7.5.5.Market size and forecast, by country
      • 7.5.5.1.Brazil market size and forecast, by test type
      • 7.5.5.2.Brazil market size and forecast, by technology
      • 7.5.5.3.Brazil market size and forecast, by application
      • 7.5.5.4.Saudi Arabia market size and forecast, by test type
      • 7.5.5.5.Saudi Arabia market size and forecast, by technology
      • 7.5.5.6.Saudi Arabia market size and forecast, by application
      • 7.5.5.7.South Africa market size and forecast, by test type
      • 7.5.5.8.South Africa market size and forecast, by technology
      • 7.5.5.9.South Africa market size and forecast, by application
      • 7.5.5.10.Rest of LAMEA market size and forecast, by test type
      • 7.5.5.11.Rest of LAMEA market size and forecast, by technology
      • 7.5.5.12.Rest of LAMEA market size and forecast, by application

CHAPTER 8:COMPANY PROFILES

  • 8.1.ABBOTT LABORATORIES
    • 8.1.1.Company overview
    • 8.1.2.Company snapshot
    • 8.1.3.Operating business segments
    • 8.1.4.Product portfolio
    • 8.1.5.Business performance
  • 8.2.BIO-RAD LABORATORIES, INC. (RAINDANCE TECHNOLOGIES, INC.)
    • 8.2.1.Company overview
    • 8.2.2.Company snapshot
    • 8.2.3.Operating business segments
    • 8.2.4.Product portfolio
    • 8.2.5.Business performance
    • 8.2.6.Key strategic moves and developments
  • 8.3.CSL LTD.
    • 8.3.1.Company overview
    • 8.3.2.Company snapshot
    • 8.3.3.Operating business segments
    • 8.3.4.Product portfolio
    • 8.3.5.Business performance
  • 8.4.DANAHER CORPORATION (CEPHEID)
    • 8.4.1.Company overview
    • 8.4.2.Company snapshot
    • 8.4.3.Operating business segments
    • 8.4.4.Product portfolio
    • 8.4.5.Business performance
    • 8.4.6.Key strategic moves and developments
  • 8.5.EUROFINS SCIENTIFIC
    • 8.5.1.Company overview
    • 8.5.2.Company snapshot
    • 8.5.3.Operating business segments
    • 8.5.4.Product portfolio
    • 8.5.5.Business performance
    • 8.5.6.Key strategic moves and developments
  • 8.6.F. HOFFMANN-LA ROCHE LTD.
    • 8.6.1.Company overview
    • 8.6.2.Company snapshot
    • 8.6.3.Operating business segment
    • 8.6.4.Product portfolio
    • 8.6.5.Business performance
    • 8.6.6.Key strategic moves and developments
  • 8.7.ILLUMINA, INC.
    • 8.7.1.Company overview
    • 8.7.2.Company snapshot
    • 8.7.3.Operating business segments
    • 8.7.4.Product portfolio
    • 8.7.5.Business performance
  • 8.8.MYRIAD GENETICS, INC. (MYRIAD RBM, INC.)
    • 8.8.1.Company overview
    • 8.8.2.Company snapshot
    • 8.8.3.Operating business segments
    • 8.8.4.Product portfolio
    • 8.8.5.Business performance
    • 8.8.6.Key strategic moves and developments
  • 8.9.QIAGEN N.V. (FORMULATRIX, INC.)
    • 8.9.1.Company overview
    • 8.9.2.Company snapshot
    • 8.9.3.Operating business segment
    • 8.9.4.Product portfolio
    • 8.9.5.Business performance
    • 8.9.6.Key strategic moves and developments
  • 8.10.THERMO FISHER SCIENTIFIC, INC.
    • 8.10.1.Company overview
    • 8.10.2.Company snapshot
    • 8.10.3.Operating business segment
    • 8.10.4.Product portfolio
    • 8.10.5.Business performance
    • 8.10.6.Key strategic moves and developments

LIST OF TABLES

  • TABLE 01.GLOBAL GENETIC TESTING MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 02.GLOBAL GENETIC TESTING MARKET FOR PREDICTIVE & PRESYMPTOMATIC TESTING, BY REGION, 2019-2027 ($MILLION)
  • TABLE 03.GLOBAL GENETIC TESTING MARKET FOR CARRIER TESTING, BY REGION, 2019-2027 ($MILLION)
  • TABLE 04.GLOBAL GENETIC TESTING MARKET FOR PRENATAL AND NEWBORN TESTING, BY REGION, 2019-2027 ($MILLION)
  • TABLE 05.GLOBAL GENETIC TESTING MARKET FOR DIAGNOSTIC TESTING BY REGION, 2019-2027 ($MILLION)
  • TABLE 06.GLOBAL GENETIC TESTING MARKET FOR PHARMACOGENOMIC TESTING, BY REGION, 2019-2027 ($MILLION)
  • TABLE 07.GLOBAL GENETIC TESTING MARKET FOR OTHER TYPES, BY REGION, 2019-2027 ($MILLION)
  • TABLE 08.GENETIC TESTING MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 09.GENETIC TESTING MARKET FOR CYTOGENETIC TESTING, BY REGION, 2019-2027 ($MILLION)
  • TABLE 10.GENETIC TESTING MARKET FOR BIOCHEMICAL TESTING, BY REGION, 2019-2027 ($MILLION)
  • TABLE 11.GENETIC TESTING MARKET FOR MOLECULAR TESTING, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 12.GENETIC TESTING MARKET FOR DNA SEQUENCING, BY REGION, 2019-2027 ($MILLION)
  • TABLE 13.GENETIC TESTING MARKET FOR OTHER MOLECULAR TESTS, BY REGION, 2019-2027 ($MILLION)
  • TABLE 14.GENETIC TESTING MARKET FOR MOLECULAR TESTING, BY REGION, 2019-2027 ($MILLION)
  • TABLE 15.GENETIC TESTING MARKET, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 16.GENETIC TESTING MARKET FOR CANCER DIAGNOSIS, BY REGION, 2019-2027 ($MILLION)
  • TABLE 17.GENETIC TESTING MARKET FOR GENETIC DISEASE DIAGNOSIS, BY REGION, 2019-2027 ($MILLION)
  • TABLE 18.GENETIC TESTING MARKET FOR CARDIOVASCULAR DISEASE DIAGNOSIS, BY REGION, 2019-2027 ($MILLION)
  • TABLE 19.GENETIC TESTING MARKET FOR OTHER APPLICATIONS, BY REGION, 2019-2027 ($MILLION)
  • TABLE 20.GENETIC TESTING MARKET REVENUE, BY REGION, 2019-2027 ($MILLION)
  • TABLE 21.NORTH AMERICA GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2019-2027 ($MILLION)
  • TABLE 22.NORTH AMERICA GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 23.NORTH AMERICA GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 24.NORTH AMERICA GENETIC TESTING MARKET REVENUE, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 25.U.S. GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2019-2027 ($MILLION)
  • TABLE 26.U.S. GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 27.U.S. GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 28.CANADA GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2019-2027 ($MILLION)
  • TABLE 29.CANADA GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 30.CANADA GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 31.MEXICO GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2019-2027 ($MILLION)
  • TABLE 32.MEXICO GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 33.MEXICO GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 34.EUROPE GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2019-2027 ($MILLION)
  • TABLE 35.EUROPE GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 36.EUROPE GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 37.EUROPE GENETIC TESTING MARKET REVENUE, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 38.GERMANY GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2019-2027 ($MILLION)
  • TABLE 39.GERMANY GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 40.GERMANY GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 41.FRANCE GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2019-2027 ($MILLION)
  • TABLE 42.FRANCE GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 43.FRANCE GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 44.UK GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2019-2027 ($MILLION)
  • TABLE 45.UK GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 46.UK GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 47.ITALY GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2019-2027 ($MILLION)
  • TABLE 48.ITALY GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 49.ITALY GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 50.SPAIN GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2019-2027 ($MILLION)
  • TABLE 51.SPAIN GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 52.SPAIN GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 53.REST OF EUROPE GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2019-2027 ($MILLION)
  • TABLE 54.REST OF EUROPE GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 55.REST OF EUROPE GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 56.ASIA-PACIFIC GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2019-2027 ($MILLION)
  • TABLE 57.ASIA-PACIFIC GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 58.ASIA-PACIFIC GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 59.ASIA-PACIFIC GENETIC TESTING MARKET REVENUE, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 60.JAPAN GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2019-2027 ($MILLION)
  • TABLE 61.JAPAN GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 62.JAPAN GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 63.CHINA GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2019-2027 ($MILLION)
  • TABLE 64.CHINA GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 65.CHINA GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 66.AUSTRALIA GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2019-2027 ($MILLION)
  • TABLE 67.AUSTRALIA GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 68.AUSTRALIA GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 69.INDIA GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2019-2027 ($MILLION)
  • TABLE 70.INDIA GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 71.INDIA GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 72.SOUTH KOREA GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2019-2027 ($MILLION)
  • TABLE 73.SOUTH KOREA GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 74.SOUTH KOREA GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 75.REST OF ASIA-PACIFIC GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2019-2027 ($MILLION)
  • TABLE 76.REST OF ASIA-PACIFIC GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 77.REST OF ASIA-PACIFIC GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 78.LAMEA GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2019-2027 ($MILLION)
  • TABLE 79.LAMEA GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 80.LAMEA GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 81.LAMEA GENETIC TESTING MARKET REVENUE, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 82.BRAZIL GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2019-2027 ($MILLION)
  • TABLE 83.BRAZIL GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 84.BRAZIL GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 85.SAUDI ARABIA GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2019-2027 ($MILLION)
  • TABLE 86.SAUDI ARABIA GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 87.SAUDI ARABIA GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 88.SOUTH AFRICA GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2019-2027 ($MILLION)
  • TABLE 89.SOUTH AFRICA GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 90.SOUTH AFRICA GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 91.REST OF LAMEA GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2019-2027 ($MILLION)
  • TABLE 92.REST OF LAMEA GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 93.REST OF LAMEA GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 94.ABBOTT: COMPANY SNAPSHOT
  • TABLE 95.ABBOTT: OERATING SEGMENT
  • TABLE 96.ABBOTT: PRODUCT PORTFOLIO
  • TABLE 97.BIO-RAD: COMPANY SNAPSHOT
  • TABLE 98.BIO-RAD: OPERATING SEGMENTS
  • TABLE 99.BIO-RAD: PRODUCT PORTFOLIO
  • TABLE 100.CSL LTD: COMPANY SNAPSHOT
  • TABLE 101.CSL LTD..: OPERATING SEGMENT
  • TABLE 102.CSL LTD..: PRODUCT PORTFOLIO
  • TABLE 103.DANAHER: COMPANY SNAPSHOT
  • TABLE 104.DANAHER: OPERATING SEGMENTS
  • TABLE 105.DANAHER: PRODUCT PORTFOLIO
  • TABLE 106.EUROFINS SCIENTIFIC: COMPANY SNAPSHOT
  • TABLE 107.EUROFINS SCIENTIFIC.: PRODUCT PORTFOLIO
  • TABLE 108.ROCHE: COMPANY SNAPSHOT
  • TABLE 109.ROCHE: OPERATING SEGMENT
  • TABLE 110.ROCHE: PRODUCT PORTFOLIO
  • TABLE 111.ILLUMINA: COMPANY SNAPSHOT
  • TABLE 112.ILLUMINA: OPERATING SEGMENTS
  • TABLE 113.ILLUMINA: PRODUCT PORTFOLIO
  • TABLE 114.MYRIAD: COMPANY SNAPSHOT
  • TABLE 115.MYRIAD: OPERATING SEGMENTS
  • TABLE 116.MYRIAD: PRODUCT PORTFOLIO
  • TABLE 117.QIAGEN: COMPANY SNAPSHOT
  • TABLE 118.QIAGEN: PRODUCT SEGMENT
  • TABLE 119.QIAGEN: PRODUCT PORTFOLIO
  • TABLE 120.THERMO FISHER SCIENTIFIC.: COMPANY SNAPSHOT
  • TABLE 121.THERMO FISHER SCIENTIFIC: PRODUCT SEGMENT
  • TABLE 122.THERMO FISHER SCIENTIFIC: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01.SEGMENTATION OF GENETIC TESTING MARKET
  • FIGURE 02.TOP INVESTMENT POCKETS, 2019
  • FIGURE 03.HIGH BARGAINING POWER OF SUPPLIERS
  • FIGURE 04.MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 05.LOW THREAT OF SUBSTITUTION
  • FIGURE 06.HIGH THREAT OF NEW ENTRANT
  • FIGURE 07.HIGH COMPETITIVE RIVALRY
  • FIGURE 08.GLOBAL GENETIC TESTING TOP PLAYER POSITIONING, 2019
  • FIGURE 09.GLOBAL GENETIC TESTING MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES
  • FIGURE 10.PATENTS REGISTERED/APPROVED IN THE WORLD, 2017-2022
  • FIGURE 11.PATENTS ANALYSIS BY YEAR, 2017 THROUGH 2022
  • FIGURE 12.YEAR 2019 PATENT ANALYSIS, BY COUNTRY
  • FIGURE 13.COMPARATIVE ANALYSIS OF GENETIC TESTING MARKET, BY PREDICTIVE & PRESYMPTOMATIC TESTING, BY REGION, 2019-2027 ($MILLION)
  • FIGURE 14.COMPARATIVE ANALYSIS OF GENETIC TESTING MARKET, BY CARRIER TESTING, BY REGION, 2019-2027 ($MILLION)
  • FIGURE 15.COMPARATIVE ANALYSIS OF GENETIC TESTING MARKET, BY PRENATAL AND NEWBORN TESTING, BY REGION, 2019-2027 ($MILLION)
  • FIGURE 16.COMPARATIVE ANALYSIS OF GENETIC TESTING MARKET, BY DIAGNOSTIC TESTING, BY REGION, 2019-2027 ($MILLION)
  • FIGURE 17.COMPARATIVE ANALYSIS OF GENETIC TESTING MARKET, BY PHARMACOGENOMIC TESTING, BY REGION, 2019-2027 ($MILLION)
  • FIGURE 18.COMPARATIVE ANALYSIS OF GENETIC TESTING MARKET, BY OTHER TYPES, BY REGION, 2019-2027 ($MILLION)
  • FIGURE 19.COMPARATIVE ANALYSIS OF GENETIC TESTING MARKET, BY CYTOGENETIC TESTING, BY REGION, 2019-2027 ($MILLION)
  • FIGURE 20.COMPARATIVE ANALYSIS OF GENETIC TESTING MARKET, BY BIOCHEMICAL TESTING, BY REGION, 2019-2027 ($MILLION)
  • FIGURE 21.COMPARATIVE ANALYSIS OF GENETIC TESTING MARKET, BY MOLECULAR TESTING, BY REGION, 2019-2027 ($MILLION)
  • FIGURE 22.COMPARATIVE ANALYSIS OF GENETIC TESTING MARKET, BY CANCER DIAGNOSIS, BY REGION, 2019-2027 ($MILLION)
  • FIGURE 23.COMPARATIVE ANALYSIS OF GENETIC TESTING MARKET, BY GENETIC DISEASE DIAGNOSIS, BY REGION, 2019-2027 ($MILLION)
  • FIGURE 24.COMPARATIVE ANALYSIS OF GENETIC TESTING MARKET, BY CARDIOVASCULAR DISEASE DIAGNOSIS, BY REGION, 2019-2027 ($MILLION)
  • FIGURE 25.COMPARATIVE ANALYSIS OF GENETIC TESTING MARKET, BY OTHER, BY REGION, 2019-2027 ($MILLION)
  • FIGURE 26.ABBOTT: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 27.ABBOTT: REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 28.ABBOTT: REVENUE SHARE, BY REGION, 2019(%)
  • FIGURE 29.BIO-RAD: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 30.BIO-RAD: REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 31.BIO-RAD: REVENUE SHARE, BY REGION, 2019 (%)
  • FIGURE 32.CSL LTD.: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 33.CSL LTD.: REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 34.CSL LTD.: REVENUE SHARE, BY REGION, 2019 (%)
  • FIGURE 35.DANAHER CORPORATION: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 36.DANAHER CORPORATION: REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 37.DANAHER CORPORATION: REVENUE SHARE, BY REGION, 2019 (%)
  • FIGURE 38.EUROFINS SCIENTIFIC.: REVENUE, 2017-2019 ($MILLION)
  • FIGURE 39.EUROFINS SCIENTIFIC: REVENUE SHARE, BY REGION, 2019 (%)
  • FIGURE 40.ROCHE: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 41.ROCHE: REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 42.ROCHE: REVENUE SHARE, BY REGION, 2019 (%)
  • FIGURE 43.ILLUMINA: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 44.ILLUMINA: REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 45.ILLUMINA: REVENUE SHARE, BY REGION, 2019 (%)
  • FIGURE 46.MYRIAD: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 47.MYRIAD: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 48.QIAGEN: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 49.QIAGEN: REVENUE SHARE, BY PRODUCT, 2019 (%)
  • FIGURE 50.QIAGEN: REVENUE SHARE, BY REGION, 2019 (%)
  • FIGURE 51.THERMO FISHER SCIENTIFIC, INC.: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 52.THERMO FISHER SCIENTIFIC, INC.: REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 53.THERMO FISHER SCIENTIFIC. REVENUE SHARE, BY REGION, 2019 (%)